articleThe LancetMar 9, 2016Closed access

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

NBNaomi B. HaasJMJudith ManolaRGRobert G. UzzoKTKeith T. FlahertyCGChristopher G. Wood

University of Pennsylvania · Dana-Farber Cancer Institute · +22 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

636
total citations
FWCI
77.37
Percentile
100%
References
31
Citations per year

Authors

25

Topics & keywords

Topics
Keywords
  • Sunitinib
  • Sorafenib
  • Medicine
  • Renal cell carcinoma
  • Placebo
  • Oncology
  • Internal medicine
  • Adjuvant
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding